FRANCISCO
VANACLOCHA SEBASTIÁN
Forscher in der Zeit 2009-2016
![Foto de FRANCISCO](/img/nophoto.png)
![Foto de Hospital Universitario Virgen de la Victoria](/img/noimage_org.png)
Hospital Universitario Virgen de la Victoria
Málaga, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen de la Victoria (19)
2019
-
Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364
2017
-
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 6, pp. 1021-1028
-
Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry
Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas dermo-sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
-
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry
Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 52-58
2016
-
Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort
Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209
-
Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis
Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602
-
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis
Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950
-
Urine metabolome profiling of immune-mediated inflammatory diseases
BMC Medicine, Vol. 14, Núm. 1
2015
-
A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk
Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881
-
Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis
Pharmacogenomics Journal, Vol. 15, Núm. 4, pp. 322-325
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time
Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643
-
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry
Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163
-
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry
Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 5, pp. 858-864
2014
-
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 7, pp. 907-914
2013
-
Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry
Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 11, pp. 1366-1374
2012
-
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials
Archives of Dermatology, Vol. 148, Núm. 4, pp. 463-470
-
Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes
Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557